Clinical trials: pMN
Splenomegaly
Spleen Size in Peripheral Blood Stem Cell Donors
This study will determine whether the spleen in people who donate stem cells (bone marrow cells collected from the blood) enlarges as a result of taking granulocyte colony-stimulating factor (G-CSF).
- Trial name
- NCT00006148
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Neuroblastoma Recurrent
Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma
An International, Single-Arm, Multicenter Phase 2 Trial.
- Trial name
- NCT04560166
- Testing
- Naxitamab and GM-CSF in combination with irinotecan and temozolomide
- Where
- 3 sites in Hong Kong, South Korea
- Volunteers
- 2 people
- Sponsor
- Y-mAbs Therapeutics
Bone Pain
Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use
G-CSF causes a release of histamine that may be a cause of chronic bone pain. Loratadine targets histamine, and so may be effective in reducing bone pain.The researchers plan to prospectively assess the effectiveness of…
- Trial name
- NCT03883386
- Testing
- Loratadine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Michigan
Hematologic Malignancies
Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support
Objectives: 1. To determine the relative toxicities, engraftment potential, kinetics of engraftment, degree of chimerism and disease control achieved with the combination of fludarabine and busulfan at different dose levels and…
- Trial name
- NCT00506857
- Testing
- Busulfan, Fludarabine
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- M.D. Anderson Cancer Center
AML
Induction With or Without Granulocyte Colony-Stimulating Factor in AML Transplantation in AML
Background The effects of granulocyte colony-stimulating factors (G-CSF) on recovery following induction chemotherapy are widely accepted. However, their impact on response and survival has not been clarified yet.
- Trial name
- TLG-AML-95-002 (NCT00820976)
- Testing
- G-CSF
- Volunteers
- 260 people
- Sponsor
- Turkish Leukemia Study Group
Neuroblastoma
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.
This is a single-arm, multicenter clinical trial conducted in patients ≥ 12 months of age with high-risk neuroblastoma in first complete response.
- Trial name
- NCT06047535
- Testing
- Naxitamab
- Volunteers
- 62 people
- Sponsor
- SciClone Pharmaceuticals
Myocardial Infarction
Myocardial Regeneration and Angiogenesis in Myocardial Infarction With G-CSF and Intra-Coronary Stem Cell Infusion
This trial was performed to evaluate the safety and the efficacy of G-CSF based stem cell therapy in patients with AMI. MAGIC Cell-1 trial enrolled patients with acute and old myocardial infarction, and had two groups of cell…
- Trial name
- NCT00307879
- Testing
- Drug: G-CSF (Dong-A pharmaceutical, Seoul, Korea), collection of mobilized peripheral blood stem cells, Intracoronary infusion of mobilized cells
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Seoul National University Hospital
Ulcerative Colitis
ADAPT Adacolumn Pediatric Trial in Ulcerative Colitis
Children aged up to 18 years with moderately active Ulcerative Colitis (PUCAI:35-64) will receive one weekly Adacolumn® apheresis treatment over 5 consecutive weeks, followed by up to 3 optional Adacolumn® apheresis treatments…
- Trial name
- NCT00781638
- Testing
- Adacolumn®
- Volunteers
- 24 people
- Sponsor
- Otsuka Frankfurt Research Institute GmbH
Neuroblastoma
Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma
The purpose of this study is to find out if an antibody called Humanized 3F8 (Hu3F8) combined with granulocyte- macrophage colony stimulating factor (GM-CSF) is safe for treating neuroblastoma.
- Trial name
- NCT01757626
- Testing
- Hu3F8 With GM-CSF
- Where
- United States
- Volunteers
- 186 people
- Sponsor
- Memorial Sloan Kettering Cancer Center